In vivo release of beta human chorionic gonadotropin by luteinizing hormone releasing hormone stimulation and its clinical application as a remission criterion in patients with gestational trophoblastic disease.
In vivo responses of trophoblasts to luteinizing hormone releasing hormone (LHRH) stimulation in 48 gestational trophoblastic disease patients were observed. Serum beta human chorionic gonadotropin (beta-hCG) levels after LHRH injection were significantly increased in patients with hCG values between 5 and 20 mIU/ml (minimal resistance group) but not in patients whose hCG levels were less than 5 mIU/ml (possible remission group). The sensitivity, specificity and the predictive values of LHRH stimulation test were 75.0, 91.3 and 95.5% in the possible remission group and 87.5, 20.0 and 77.8% in the minimal resistance group.
Kim
S J
SJ
Department of Obstetrics and Gynecology, Catholic University Medical College, Seoul, Korea.
Jung
J K
JK
Kang
B C
BC
Namkoong
S E
SE
Lee
J W
JW
D006063:Chorionic Gonadotropin / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D010446:Peptide Fragments / Q000097:blood*; D011247:Pregnancy; D011379:Prognosis; D011863:Radioimmunoassay; D013997:Time Factors; D014328:Trophoblastic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000628:therapy
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D007987:Gonadotropin-Releasing Hormone